inotuzumab ozogamicin   Click here for help

GtoPdb Ligand ID: 8266

Synonyms: Besponsa® | CMC-544
Approved drug Immunopharmacology Ligand
inotuzumab ozogamicin is an approved drug (EMA & FDA (2017))
Compound class: Antibody
Comment: Inotuzumab ozogamicin is an antibody-drug conjugate (ADC) that targets delivery of the highly cytotoxic ozogamicin (a derivative of calicheamicin γ1) to CD22 (SIGLEC-2) +ve myeloid cells [1]. The calicheamicin derivative is N-acetyl gamma calicheamicin dimethylhydrazide as reported by DiJoseph et al (2004) [1].
Click here for help
Immunopharmacology Comments
Inotuzumab ozogamicin is an immuno-oncology drug that blocks the inhibitory SIGLEC-2/sialic acid-containing glycans B cell checkpoint, an action that restores immune cell activation, and simultaneously delivers a toxic payload to CD-22-targeted cancer cells.
Immunopharmacology Disease
Disease X-Refs Comment References
Acute lymphocytic leukemia (ALL) OMIM: 613065
Approved therapy for ALL.